Lyndra Therapeutics is pioneering long-acting oral therapies through its proprietary LYNX™ drug delivery platform, with the potential to revolutionize oral drug delivery by providing week-long or longer dosing in an oral form. The company's core purpose is to reinvent medicine for a healthier world, and it has achieved rapid progress in formulating therapies and advancing products to the clinic.

Amy Schulman

Andrew Bellinger

Colin R. Gardner

Giovanni Traverso

Lyndra Therapeutics

Welcome to Lyndra Therapeutics: Medicine, reinvented
 
Imagine taking a week’s worth of medicine in a single dose, once a week. Four pills a month. Eventually, one pill a month. Lyndra Therapeutics’ LYNX™ drug delivery platform is making that possible.
 
Lyndra Therapeutics is a clinical-stage biopharmaceutical company pioneering long-acting oral therapies. Lyndra is focused on commercializing therapies in central nervous system (CNS) disorders, with lead product candidate oral weekly risperidone (LYN-005) for the treatment of people living with schizophrenia and bipolar 1 disorder. The company is also committed to advancing its platform to tackle major public health and global health challenges, with therapies including oral weekly levomethadone and oral weekly buprenorphine for opioid use disorder, a monthly oral contraception pill and oral biweekly ivermectin for malaria eradication.
 
Since its founding, partners have included the Bill & Melinda Gates Foundation, the NIH, AbbVie and Gilead Sciences, Inc. Lyndra is headquartered in Watertown, MA and has a state-of-the-art GMP manufacturing facility in Lexington, MA.
 
Core purpose: reinvent medicine for a healthier world
 
Core values: value every voice; resilient to the core; I contribute, we deliver
 
Does Lyndra sound like a great fit for you? Join the Team: https://lyndra.com/about/join-the-team/

AIG Investments

Polaris Partners

Quark Venture

Limitless Ventures

Mass General Brigham Ventures

THE CATALYTIC IMPACT FOUNDATION (CIF)

Yipinhong Pharmacy

Gilead Sciences

HOPU Investment Management Company

ImpactAssets

Sarissa Capital Management

Sun Pharmaceutical Industries

At Lyndra, our team is eager to bring long-acting oral therapies to people who need them. Today, we announced positive data from our pivotal phase 3 study of oral weekly risperidone (LYN-005) for schizophrenia. As our Chief Medical Officer and President of Global Product Development, Richard Scranton MD MPH shared, “These positive data demonstrate that a single dose of oral weekly risperidone delivers comparable medication levels to daily risperidone, validating that Lyndra’s LYNX® drug delivery platform may provide a medication option that significantly reduces dosing frequency. For people who rely on risperidone as part of their treatment regimen, oral weekly risperidone could vastly improve medication adherence and outcomes.”

This is a major step forward towards our goal of bringing long-acting oral medicines based on the LYNX drug delivery platform to the people who need them most and transforming how we take medicines. 

At Lyndra, we are passionate about building a healthier world through long-acting oral therapies. Today, we announced the close of a $101 Million Series E funding round to support that mission, led by Sarissa Capital Management LP and including SUN PHARMA and Polaris Partners These funds will support the development of therapies with our LYNX® drug delivery platform, including oral weekly risperidone (LYN-005), which is nearing completion of phase 3 clinical study.

“We appreciate the support our investors are providing as we complete our risperidone phase 3 trials and continue the development of our pipeline of oral weekly therapies through this round of financing,” said Jessica Ballinger, Lyndra President and CEO. “This investment validates the LYNX platform and moves us forward in our plans to bring our lead product candidate, oral weekly risperidone, through the regulatory pathway and to patients.”


We’re honored to share that our President & CEO, Jessica Ballinger , has been recognized in this year’s PharmaVoice Top 100. Congratulations, Jess! 

To learn more visit: https://lnkd.in/gwb4f7Rz
#leadership #pharmavoice100 #trailblazer 

August 31st marks International Overdose Awareness Day. As such, we honor those who have lost their lives to the drug overdose epidemic and acknowledge the grief of family and friends left behind. As a company working to create long-acting oral medications for people living with opioid use disorder with support from The National Institutes of Health’s The National Institute on Drug Abuse (NIDA), we want to take the time to remember the lives lost to the drug overdose epidemic. We look towards a future where people living with addiction have access to the help they need. #NIH #NIDA

Metric
Company Name	Lyndra Therapeutics
Symbol
MSH ID	COM:LYNDRA
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biopharmaceuticals
Country	US
Stage	Series E
Employee Count	90
Website	lyndra.com
LinkedIn	lyndra
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	3.77K
Web Traffic Growth	93.35
Valuation
Raised Capital	101M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:LYNDRA

Lyndra Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue